Immunovant (IMVT) is up about 7% to roughly $29.30 as momentum traders push the shares through the top of their recent range following a new 52-week high print around $29.27 on April 17, 2026. With the stock sitting near its yearly peak, incremental demand can have an outsized effect as investors chase strength and systematic strategies respond to breakout price action. (investing.com)

The rally is also supported by a constructive analyst backdrop in April, with multiple firms maintaining ratings and targets, including bullish targets that sit well above the current price. Recent published estimates show a “Buy” leaning consensus and an average target around $40, alongside recent April actions from firms such as Goldman Sachs, Truist, Leerink Partners and Oppenheimer. (investing.com)

IMVT has also carried notable short interest, which can intensify upside moves when price breaks higher and shorts reduce exposure into strength. Recent short-interest data show a large short position and a high days-to-cover figure, a setup that can contribute to fast intraday jumps when buyers press the stock near highs. (optionsanalysissuite.com)

Near term, traders will watch whether IMVT can hold above the prior resistance area around the $29 level after tagging a new 52-week high, and whether fresh company updates or additional analyst actions emerge to extend the move. Investors will also be focused on continued progress across the IMVT-1402 program, since the stock’s premium valuation and momentum are closely tied to confidence in execution and upcoming clinical milestones. (investing.com)